BEGIN:VCALENDAR VERSION:2.0 PRODID:-//IBSAL - ECPv6.17.4.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:IBSAL X-ORIGINAL-URL:https://ibsal.es/en/ X-WR-CALDESC:Events for IBSAL REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD TZOFFSETFROM:+0000 TZOFFSETTO:+0000 TZNAME:UTC DTSTART:20240101T000000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:Europe/Helsinki BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20251026T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20260329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20261025T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20270328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20271031T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20280326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20281029T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;VALUE=DATE:20250326 DTEND;VALUE=DATE:20300604 DTSTAMP:20251114T074015Z CREATED:20250304T093623Z LAST-MODIFIED:20251114T074015Z UID:10002030-1742947200-1906761599@ibsal.es SUMMARY:Diverse and responsible health DESCRIPTION:The project “Diverse and Responsible Health” aims at the scientific dissemination of the IBSAL among the LGTBI+ population of Salamanca. Through a series of workshops scheduled throughout 2025\, various key issues for the health of this group will be addressed\, promoting a gender and diversity perspective in medical and scientific research. \nThese workshops\, led by the Eros Service of Asociación Iguales\, will have the participation of specialized professionals\, IBSAL research staff and collaborating entities. The program includes four sessions with the following topics: \n\n\n\n\nITS: Why do they always point the finger at us? – Analysis of sexually transmitted infections in the LGTBI+ population and the need for a person-centered approach.\n\n  \nDate: Wednesday\, March 26\, 2025\, at 7:00 p.m. \nPlace: La Vegatería (C/ Gütenberg\, 13\, 37007 Salamanca) \nIBSAL Researchers: Moncef Belhassen and Virginia Velasco \nFree admission \n  \n \n  \n\nChemSex: an emerging phenomenon or an old acquaintance? – Study of ChemSex and its impact on health from a community perspective.\n\n  \nMore information coming soon. \n  \n\nLifestyles in queer people – Promotion of healthy habits and analysis of health determinants in the LGTBI+ population.\n\n  \nMore information coming soon. \n  \n\nMental health: how to take better care of ourselves – Minority stress\, discrimination and other barriers that affect the mental health of minorities.\n\n  \nMore information coming soon. \n  \nEach workshop will combine the presentation of specialists in the field with the participation of IBSAL research staff\, bringing scientific research closer to the community. \nThe project has the collaboration of several local entities and is supported by the University of Salamanca\, the City Council of Salamanca and the IBSAL. URL:https://ibsal.es/en/evento/diverse-and-responsible-health/ LOCATION:La Vegatería\, 13 Gütenberg Street\, Salamanca\, Salamanca\, 37007\, Spain CATEGORIES:Disclosure ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2025/03/Logo-Iguales-Tagline-Color.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251124T061504Z CREATED:20251124T061504Z LAST-MODIFIED:20251124T061504Z UID:10002268-1767225600-1830383999@ibsal.es SUMMARY:PARTNERSHIP: European Partnership on One Health and Antimicrobial Resistance (OH AMR) DESCRIPTION:Features\nThe first joint transnational call for proposals from the EUP OHAMR Partnership on Antimicrobial Resistance\, titled “Treatments and Adherence to Treatment Protocols” \nThe goal of this call for proposals is to improve treatment success rates in patients\, animals\, and plants affected by bacterial or fungal infections by offering new treatment options while reducing the risk of resistance development across the various settings of the “One Health” approach . \nThe call for proposals is co-financed by the European Union and involves 37 funding organizations from 28 countries\, with a total estimated budget of more than 31 million euros. \nIn addition\, the following national and regional funding agencies are participating in this call for proposals: the Aragon Institute of Health Sciences (IACS)\, the State Research Agency (AEI)\, and the Carlos III Health Institute (ISCIII). \nRequirements\nProposals must address one of the following topics: \nTopic 1: Identify and develop new combination therapies using existing or innovative antimicrobials\, or antimicrobials in combination with adjunctive therapies\, to extend drug efficacy and combat resistance. \nTopic 2: Develop tools and methods to improve adherence to treatment protocols. \nTopic 3: Assess the impact of antimicrobials used in veterinary and agricultural settings on the risk of AMR transmission to humans and the environment\, to inform policies on restricting certain antimicrobials for human use. \n\nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 18\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 2\, 2026\, (1:00 p.m. CET)\n\n\nNotification of the Results of the Pre-Proposal\nApril 29\, 2026\n\n\nDeadline for full proposals\nJune 17\, 2026\, (1:00 p.m. CET)\n\n\nFinal Funding Recommendation Announced\nOctober 30\, 2026\n\n\nProjects begin\nDecember 2026–April 2027\n\n\n\n  \n  URL:https://ibsal.es/en/evento/partnership-european-partnership-on-one-health-and-antimicrobial-resistance-oh-amr-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251124T120728Z CREATED:20251124T120728Z LAST-MODIFIED:20251124T120728Z UID:10002252-1767225600-1830383999@ibsal.es SUMMARY:ERA4HEALTH Partnership DESCRIPTION:Features\nThe ERA4HEALTH partnership has published a joint transnational call \, “Prevent-OO: Understanding and Preventing Overweight and Obesity” Mechanisms of their onset and progression\, neglected determinants\, and novel strategies for critical transitional periods in life. \nThe call for proposals seeks to identify and implement innovative and holistic preventive and public health strategies to address obesity\, taking into account environmental\, psychological\, and socioeconomic factors to promote healthier lifestyles. In addition\, ERA4Health fosters transnational and interdisciplinary collaborations with a translational approach to generate new knowledge and develop effective prevention strategies. \nThe call for proposals is co-financed by the European Union and involves 25 funding organizations from 20 countries\, with a total estimated budget of more than 18 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nApplications must cover only one of the two topics listed below and address at least one of the two specified subtopics (subtopic 1a and/or 1b for topic 1\, and subtopic 2a and/or 2b for topic 2); both topics and subtopics are equally relevant for this call: \n1. Understanding the causes of obesity and overweight and their complications through mechanistic research \n1a. To investigate biological mechanisms—including chronobiological\, genetic\, and/or epigenetic mechanisms—underlying the onset and progression of overweight and obesity\, as well as related diseases. Secondary factors that may influence these biological mechanisms—such as the living environment\, lifestyle\, or psychological status—should also be considered where relevant. \n1b. To investigate how being overweight and obesity contribute to the development of related clinical complications and/or affect the mechanism of action of treatments for other diseases or disorders. \n2. Prevention and public health strategies for critical transitional periods of life. Both subtopics 2a. and 2b. should address critical transitional periods of life only. The choice of the critical transitional periods of life to be studied must be clearly justified in the proposal. These periods should result from biological changes (e.g.\, postpartum\, menopause\, andropause) or socio-environmental changes (e.g.\, the period between pregnancies\, diagnosis of a chronic disease\, recovery from illness\, retirement\, etc.). \n2a. To understand and address neglected determinants—including their interdependence—in the onset and progression of overweight and obesity during transitional periods of life. \n2b. To develop novel tools or preventive strategies that can be implemented to prevent the onset and progression of overweight and obesity during transitional periods of life\, taking into account physiological\, pathophysiological\, psychological\, and behavioral influences and/or the socioeconomic status of citizens/patients. Importantly\, the proposal should include an assessment of the economic impact of the proposed tools or strategies on the healthcare system and provide recommendations to help policymakers define new regulations and guidelines to prevent overweight and obesity. \n\nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 13\, 2025\n\n\nDeadline for Pre-Proposals\nJanuary 21\, 2026\, (12:00 CET)\n\n\nNotification of the Results of the Pre-Proposal\nApril 13\, 2026\n\n\nDeadline for full proposals\nJune 11\, 2026\, (12:00 CET)\n\n\nRebuttal Phase\nAugust 24\, 2026\n\n\nProjects begin\nDecember 2026–May 2027\n\n\n\n  \n  URL:https://ibsal.es/en/evento/era4health-partnership-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251126T071112Z CREATED:20251126T071112Z LAST-MODIFIED:20251126T071112Z UID:10002178-1767225600-1830383999@ibsal.es SUMMARY:PARTNERSHIP European Partnership for Personalized Medicine (EP PerMed) DESCRIPTION:Features\nA joint transnational call for proposals has been published by the European Partnership for Personalized Medicine (EP PerMed)\, Joint Transnational Call (JTC) 2026: Personalized Medicine for Cardiovascular\, Metabolic\, and Kidney Diseases (CARMEN2026) \nThis call for proposals will fund human health research projects on innovative personalized medicine strategies for patients with cardiovascular\, metabolic\, or kidney diseases. Research projects may focus on a single disease or address these conditions in combination. \nResearch projects that combine a personalized medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular\, metabolic\, and renal diseases will be viewed favorably. \nThe call for proposals is co-funded by the European Union and involves 39 funding organizations from 27 countries\, with a total estimated budget of over 38 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nProposals should address one or more of the following aspects: \n\nDevelopment and validation of innovative\, personalized therapeutic approaches for cardiovascular\, metabolic\, or kidney diseases through testing in relevant preclinical models (e.g.\, human cell cultures\, organoids\, organs-on-chips\, disease-specific animal models\, or in silico models).\nIdentification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to monitor treatment response in patients with cardiovascular\, metabolic\, or kidney diseases in order to tailor treatment pathways. This may include the analysis of treatment effectiveness or treatment-related (including those associated with multiple medications) adverse effects\, as well as dose optimization. \nIdentification and validation of stratifying molecular markers or signatures\, or stratifying diagnostic technologies\, for the early prediction of disease risk and the prevention of disease progression or comorbidities in patients with cardiovascular\, metabolic\, or kidney diseases\, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.\n\n  \nResearch projects that combine a personalized medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular\, metabolic\, and kidney diseases are welcome. \nProjects funded under this call are also required to include a dedicated work package focusing on the translation or implementation of research outcomes into clinical practice\, with an emphasis on\, for example\, patient outcomes\, patient preferences\, costs\, reimbursement\, education (for healthcare providers\, patients\, and citizens)\, ELSA (ethical\, legal\, and societal aspects)\, or accessibility at the point of care. \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 25\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 10\, 2026\, (2:00 p.m. CET)\n\n\nNotification of the Results of the Pre-Proposal\nMay 5\, 2026\n\n\nDeadline for full proposals\nJune 9\, 2026\, (2:00 p.m. CET)\n\n\nRebuttal stage\nMid- to late August 2026\n\n\nNotification of Funding Decisions\nOctober 2026\n\n\n\n  \n  URL:https://ibsal.es/en/evento/partnership-european-partnership-for-personalized-medicine-ep-permed/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251215T081017Z CREATED:20251215T081017Z LAST-MODIFIED:20251215T081017Z UID:10002206-1767225600-1830383999@ibsal.es SUMMARY:PARTNERSHIP: Transforming Health and Care Systems (THCS) DESCRIPTION:Features\nA joint transnational call for proposals has been published by the Transforming Health and Care Systems (THCS) partnership\, Joint Transnational Call for Proposals (2026) on Access to Care. \nThis call for proposals promotes the coordination and optimization of research and innovation efforts to support the necessary transformation of health and social care systems in Europe and partner countries. Its goal is to fund projects that help ensure equitable access to and appropriate use of health and care services\, providing policymakers and decision-makers with the knowledge and tools needed to reallocate resources effectively. \nThe projects\, based on existing evidence\, will develop innovative solutions to reduce inequalities in access to care by addressing financial models\, service delivery models\, and integrated and interdisciplinary care programs at all levels of the system. \nThe call for proposals is co-financed by the European Union and involves 32 funding organizations\, with a total estimated budget of more than 35 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nThe aim of the call is to fund research and innovation projects that\, within an ecosystem approach\, contribute to ensuring equitable access to and use of health and care services. Through the funded research and innovation projects\, policymakers and decision-makers should gain the knowledge and tools necessary to implement the reallocation of resources as the health and care system undergoes a transition to address new and ongoing challenges. \nAll proposals would benefit from co-creation with stakeholders\, particularly people from disadvantaged groups. Proposals are encouraged to incorporate elements of the social sciences as part of an interdisciplinary approach. \nThis call requires collaborative\, transnational research\, innovation\, and evaluation activities. It is mandatory to engage in one or more of the following types of activities: applied research\, implementation research\, piloting\, upscaling\, and/or testing. All projects must demonstrate proof of concept(s)\, validate concepts\, models\, or solutions\, and showcase demonstrations of solutions in relevant health and care ecosystems. The adaptation of already adopted solutions to other settings is also within the scope of this call. \n  \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 21\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 2\, 2026\, (2:00 p.m. CET)\n\n\nCall for Full Proposals\nStarting May 11\, 2026\n\n\nDeadline for full proposals\nJune 30\, 2026\, (2:00 p.m. CET)\n\n\nRebuttal stage\nSeptember 2026\n\n\nNotification of Funding Decisions\nLate October 2026\n\n\n\n  \n  URL:https://ibsal.es/en/evento/partnership-transforming-health-and-care-systems-thcs/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20270101 DTSTAMP:20260112T060813Z CREATED:20260112T060813Z LAST-MODIFIED:20260112T060813Z UID:10002251-1767225600-1798761599@ibsal.es SUMMARY:Reticular Model of Organization and Community Care for People with Mental Illness DESCRIPTION:Coeducational Course: “Reticular Model of Organization and Community Care for People with Mental Illness“ \n  \nObjective: \nTo explain how the network-based model for organizing mental health services and facilities works\, with a focus on the coordination of social and health care services and between mental health and primary care. \n  \nSpecific objectives: \n\nBecome familiar with all the health and social care services integrated into the mental health social-health care network under the network model. Describe the operations and objectives of the Assertive Community Treatment Unit. Conduct a study to develop a feasible proposal for implementation in your workplace.\nTo understand the changes introduced by the model to improve the quality of care in the field of mental health. \nIdentify the epistemological and organizational foundations of the model and its implementation in a healthcare region such as Zamora. \nTo lay the groundwork for coordination among distinct care networks—such as social-health\, social\, and health care networks—as well as to define the new roles of workers within these networks.\n\nDate: \nFrom August 1 to December 31\, 2025. \n  \nLocation: \nOnline and the Zamora Mental Health Department. \n  \nEnrollment: \n  \nRegistration is open throughout the academic year on an individual basis via our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \nPrice: \n50 euros (USAL students\, PhD students\, IBSAL members\, students from developing countries\, primarily in Latin America). \n150 euros (general admission). \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/reticular-model-of-organization-and-community-care-for-people-with-mental-illness/ LOCATION:Online\, Online CATEGORIES:Course END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260210 DTEND;VALUE=DATE:20260916 DTSTAMP:20260225T064245Z CREATED:20260225T064245Z LAST-MODIFIED:20260225T064245Z UID:10002238-1770681600-1789516799@ibsal.es SUMMARY:Horizon Europe. Cancer Mission 2026 and 2027 DESCRIPTION:Features\nThe work program for the Cancer Missions under Horizon Europe for 2026 and 2027. \nThese are single-phase calls for proposals\, aimed at international multidisciplinary consortia\, which must submit a proposal in accordance with the specifications for each topic. \nAdmission requirements\, eligibility criteria\, and the necessary documents are described in the General Annexes. \n  \nThese are the topics included in the Cancer Mission’s new Work Program for the year 2026: \nThese topics are single-phase: they begin on February 10\, 2026\, and end on September 15\, 2026. \nHORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research \nHORIZON-MISS-2026-02-CANCER-02: Microbiome for Early Cancer Prediction Before the Onset of Disease \n\nHORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimize immunotherapy interventions for patients with refractory cancers \nHORIZON-MISS-2026-02-CANCER-04: Earlier and More Precise Palliative Care \nHORIZON-MISS-2026-02-CANCER-05: Improving the mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) \nHORIZON-MISS-2026-02-CANCER-06: Development of a research capacity-building program on cancer with and for Ukraine (csa) \nHORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of Older Cancer Patients \n\nA very interesting topic in the “Soil Deal for Europe” section\, which opens on February 4\, 2026\, and closes on September 23\, 2026: \nHORIZON-MISS-2026-05-SOIL-02: Antimicrobial Resistance and Antibiotic Biosynthesis in Soils: Developing Key Insights and Countermeasures Using a One-Health Approach \n  \nThese are the topics included in the Cancer Mission’s new Work Program for the year 2027: \nThese topics are single-phase: they begin on February 10\, 2027\, and end on September 21\, 2027. \nHORIZON-MISS-2027-02-CANCER-01: Leveraging functional genomics to identify novel targets for cancer treatment \nHORIZON-MISS-2027-02-CANCER-02: Clinical research conducted by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers \nHORIZON-MISS-2027-02-CANCER-03: Phase 1\, including first-in-human clinical trials to test biomarker-guided medicines or multimodal treatment interventions for patients with rare or very rare cancers or cancer subtypes \nHORIZON-MISS-2027-02-CANCER-04: Improving equitable health outcomes and added value for and with cancer patients through health economics research\, health systems research\, and outcomes research \nHORIZON-MISS-2027-02-CANCER-05: Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies\, cancer medical devices\, or cancer medicines \nHORIZON-MISS-2027-02-CANCER-06: Support for a research program on the quality of life (QoL) of young cancer survivors\, led by cancer charities and funding agencies (csa) \nThis is a very interesting topic—a Joint Call for Missions. The call opens on February 4\, 2027\, and closes on September 21\, 2027: \nHORIZON-MISS-2027-06-SOIL-CANCER: Living labs to monitor and mitigate carcinogenic substances in and originating from soils: Evaluating their effects on human cancer risks \n  \n**If you’re interested in any of our job openings or need more information\, please don’t hesitate to contact us. \n\n\n\nRequirements:\nThese calls for proposals are aimed at multidisciplinary European consortia. Unless otherwise specified in the specific conditions of the call\, only legal entities that form a consortium will be eligible to participate in the actions\, provided that the consortium includes\, as beneficiaries\, three legal entities that are independent of one another\, each established in a different country\, in accordance with the following criteria: \n\n\nat least one independent legal entity established in a Member State; and \n\n\nat least two other independent legal entities\, each established in different Member States or Associated Countries. \n\n\nLegal entities established in Russia\, Belarus\, or in territories of Ukraine not controlled by the government are not eligible. \nHow to apply\nApplications consist of two sections: \n-Part A (to be completed online) contains administrative information related to the consortium\, the budget\, and specific details of the call for proposals. \n-Part B (a template downloaded from the Commission’s website must be completed) contains the scientific and technical aspects of the project. \n  \nSubmission deadline.\nThe 2026 application deadlines are September 15\, and the process is a single-stage process\, With the exception of call HORIZON-MISS-2026-05-SOIL-02\, which ends on September 23\, 2026. \nThe application deadlines for 2027 are September 21\, 2027\, and the application process consists of a single stage. URL:https://ibsal.es/en/evento/horizon-europe-cancer-mission-2026-and-2027/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260226 DTEND;VALUE=DATE:20261029 DTSTAMP:20260804T112434Z CREATED:20260601T085642Z LAST-MODIFIED:20260804T112434Z UID:10002348-1772064000-1793231999@ibsal.es SUMMARY:European Innovation Council (EIC) Pathfinder Challenges DESCRIPTION:Features\nThe Commission’s EIC Pathfinder program supports early-stage\, disruptive technological innovations with revolutionary potential. \nFrom the conception of an idea to proof of concept (TRL 1–4)\, the EIC Pathfinder\, as part of the EIC’s Horizon Europe work program\, funds innovative technologies with a transformative impact. It offers two funding options: Open and Challenges\, the latter of which is aimed at specific objectives defined by the EIC and is currently open for applications. \nRequirements:\nThe budget is 96 million euros\, and the topics are: specific challenges of EIC Pathfinder. \nThe following is a list of topics with links: \n\nPathfinder Challenge 1: Advanced Materials for Miniaturized Energy Harvesting Systems: to support the next generation of energy-autonomous systems and IoT devices. Advanced Materials for Miniaturized Energy Harvesting Systems. \nPathfinder Challenge 2: Biotechnology for Healthy Aging: Develop biotechnological or pharmaceutical interventions to prevent\, delay\, or reverse age-related diseases. Biotechnology for Healthy Aging\nPathfinder Challenge 3: DeepRAP: Deep Reasoning\, Abstraction\, and Planning for Trustworthy Cognitive AI Systems: Promoting trustworthy cognitive AI through deep reasoning\, abstraction\, and planning. DeepRAP: Deep Reasoning\, Abstraction & Planning towards trustworthy Cognitive AI Systems\n\n  \nThey are European consortia consisting of at least two entities from different countries or a single legal entity established in a Member State or an associated country. \nEligible applicants include: research organizations and universities\, as well as startups and small and medium-sized enterprises (SMEs) developing high-risk\, high-impact technologies. \nMid- and large-cap companies may not apply as lead applicants. \n  \nProposals are scored (0–5) based on three criteria: \n\nExcellence: ambition\, innovation\, and a high-risk/high-return vision.\nImpact: potential to lay new foundations for innovative technologies.\nImplementation: quality of the consortium and the work plan.\n\n  \nTie-breaking criteria: higher scores for excellence and impact\, gender balance\, and participation by SMEs and countries with the highest participation rates. \nAll essential research-related expenses\, including those for personnel\, equipment\, travel\, and subcontracting\, are covered under the lump-sum grant. \nSubmission Deadline\nThe deadline is October 28\, 2026. URL:https://ibsal.es/en/evento/european-innovation-council-eic-pathfinder-challenges/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260331 DTEND;VALUE=DATE:20260926 DTSTAMP:20260518T065918Z CREATED:20260518T065918Z LAST-MODIFIED:20260518T065918Z UID:10002263-1774915200-1790380799@ibsal.es SUMMARY:CDTI Eureka Biotech Call 2026 DESCRIPTION:Features\nThe CDTI and the Eureka program are launching their international call for proposals\, the Eureka Biotech Call 2026\, an initiative aimed at promoting international collaborative R&D projects focused on developing innovative solutions in the field of biotechnology. \n\nSeventeen countries and regions are participating in the call for proposals: Austria\, Belgium (Flanders and Wallonia)\, Canada\, Chile\, Estonia\, France\, Germany\, Lithuania\, the Netherlands\, Singapore\, South Africa\, South Korea\, Spain\, Sweden\, Switzerland\, and Turkey. \n\nThis call for proposals represents an excellent opportunity to promote international collaborative projects with a clear market focus and high potential for industrial implementation in the biotechnology sector. Proposals may address a wide range of research and innovation areas related to: \n\nAdvanced Biomanufacturing and Enabling Technologies for Biotechnology Ecosystems\nNext-Generation Therapies and Treatments\nAgricultural and Veterinary Innovations\nAdvanced Diagnostics and Data-Driven Technologies\nBioinformatics\, Artificial Intelligence\, and Digitalization Applied to Biotechnology\nBioprocess Technologies and Sustainable Bioindustrial Solutions\n\n  \nApplication areas include\, among others: \n\nHealth and Medicine\nPharmaceuticals and Advanced Therapies\nIndustrial Biotechnology\nAgriculture and Food\nDiagnostics and Medical Devices\nBioeconomy and Sustainability\nDigital Health and Biological Data Analysis\n\n  \nThe call for proposals will feature activities and international networking tools to facilitate the identification of partners and the formation of collaborative consortia among companies\, startups\, universities\, and technology centers interested in developing joint projects. \nRequirements:\nThis call for proposals is aimed at market-oriented R&D projects involving experimental development activities and with technology readiness levels primarily ranging from TRL 5 to TRL 7. The participation of at least two independent entities from two different participating countries will be required\, with companies playing a significant role within the international consortia. \nThe minimum budget for each company is €175\,000. There is no budget limit for Spanish partners\, but the budget must be commensurate with the activities to be carried out and the company’s capacity. \nThe Spanish company (or the Spanish consortium coordinator\, where applicable) must submit a formal application for funding for the international R&D project through the CDTI’s online portal by October 2\, 2026. The application must include the Eureka Application Form (in English) and\, when available\, a draft of the consortium agreement. The signed consortium agreement must be submitted before the Eureka label is granted. \nOnce the international application has been received\, CDTI will verify the eligibility of the Spanish applicants. If they are deemed eligible\, CDTI will process the corresponding national funding applications for each Spanish participant. These applications must be completed and duly submitted by all Spanish partners within the deadline set by CDTI\, approximately one month after the call’s deadline. \nDepending on the funding instrument requested\, CDTI may require the submission of additional documentation in Spanish. Spanish partners who do not submit the required applications by the established deadlines may be excluded. \nFunding for startups\, SMEs\, and large companies covers up to 85% of the project’s eligible costs. \nIBSAL (a research center) and universities are participating as subcontractors in the project. \nHow to apply\nThe deadline for submitting applications is September 25\, 2026\, at 11:59 p.m. CEST. \nProject start date: second quarter of 2027 \nYou can find all the information about the objectives\, eligibility requirements\, application process\, and funding for this call at the following link: Eureka Biotech Call 2026. \n  URL:https://ibsal.es/en/evento/cdti-eureka-biotech-call-2026/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260421 DTEND;VALUE=DATE:20270116 DTSTAMP:20260518T124654Z CREATED:20260518T124654Z LAST-MODIFIED:20260518T124654Z UID:10002294-1776729600-1800057599@ibsal.es SUMMARY:Call for Applications: INVESMIR SEC-CNIC Training Program 2026 DESCRIPTION:Purpose\nThe INVESMIR SEC-CNIC Program aims to supplement the training of medical professionals during their hospital residency by facilitating the development of a research project in the CNIC laboratories under the supervision of a CNIC scientist. \nThis program also aims to establish the necessary connections and partnerships so that\, upon completing their specialization\, these professionals can continue to develop their research projects at their respective hospitals\, with the support of the SEC and the CNIC. \n  \nTerms and Conditions\nA maximum of 10 spots will be awarded for the INVESMIR SEC-CNIC training program in the 2026 call for applications. \nThe potential recipient groups for the CNIC under this program and information regarding their research areas are available at the following link:\nhttps://www.cnic.es/es/investigacion/laboratorios \nInterested individuals must contact the research groups and be accepted into one of them in order to apply.\nIn all cases\, the training stints will be full-time. \nParticipants from hospitals outside the Community of Madrid will have their travel expenses to Madrid covered up to a maximum of 300 € (one round-trip from their usual place of residence; if traveling by public transportation\, it must be in economy class\, in accordance with the CNIC’s travel policy). In addition\, these participants will be reimbursed for accommodation expenses in Madrid up to a maximum of 250 euros per week. Any amounts exceeding the weekly limit will be offset against one another\, provided they do not exceed 1\,000.00 € over a four-week period. \nAll expenses must be supported by documentation\, including invoices issued in the participant’s name and proof of payments made from their bank account. The documentation must be sent in a single email to programa_formación@cnic.es within 10 calendar days after the end of the stay at the Center. Once the documentation has been reviewed\, the participant will be notified of which supporting documents must be submitted as original hard copies (invoices\, receipts\, or other supporting documents) and mailed to the Center’s address. \nParticipation in the internship will not entail any type of contractual relationship between the intern and the CNIC. \n  \nDuration and Length of Stay\nThe duration of the stay will be flexible\, ranging from 4 to 6 months\, in accordance with the regulations set forth in the MIR Training Program of the participant’s home hospital.\nStays must take place entirely between June 1\, 2026\, and May 31\, 2027\, except in exceptional circumstances duly authorized by the CNIC and SEC management. \n  \nRequirements\nBe a member of the Spanish Society of Cardiology (SEC).\nBe a medical professional\, of any nationality\, currently in the R3\, R4\, or R5 years of a residency program in Cardiology or Cardiovascular Surgery at a hospital in Spain. \n  \nDeadline and Formalization\nThe call for applications will be open from April 21\, 2026\, through January 15\, 2027.\nApplications must be submitted exclusively through the CNIC online system:\nhttps://www.cnic.es/es/convocatoria/invesmir-sec-cnic\, and the following documentation must be attached: \n\nResume.\nNational Identity Card.\nDocument verifying your personal Social Security number (those issued by mutual insurance companies are not valid).\nA signed authorization from the Academic Committee of the training program at the participant’s home hospital\, expressly stating the dates of the stay.\nLetter of Acceptance from the CNIC Supervising Researcher Responsible for the Stay\nBrief description of the proposed research project for the residency\nCertificate of residence for candidates residing in Spain outside the Community of Madrid.\n\nDocuments must be attached to the form in PDF format. \nFollowing the publication of the call for applications\, applications will be reviewed on the 15th of each month. Each applicant will then be notified by email whether their application has been accepted or\, if applicable\, the reasons for requiring corrections or for exclusion. Applicants in the correction phase may correct the errors that led to the rejection of their application within a maximum period of 5 days\, starting the day after the notification date. The decision regarding admission to or exclusion from the evaluation process will be communicated through the same procedure. \nElectronic signatures will be used throughout the selection process and the subsequent hiring procedures; therefore\, applicants must have a digital ID (DNIe) or a recognized electronic certificate issued by a registered certification authority (https://sedeaplicaciones.minetur.gob.es/Prestadores/)\, such as the one issued by the National Mint and Stamp Factory. \nTERMS AND CONDITIONS OF THE CALL FOR APPLICATIONS URL:https://ibsal.es/en/evento/call-for-applications-invesmir-sec-cnic-training-program-2026/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260501 DTEND;VALUE=DATE:20270101 DTSTAMP:20260518T094535Z CREATED:20260518T094535Z LAST-MODIFIED:20260518T094535Z UID:10002280-1777593600-1798761599@ibsal.es SUMMARY:EATRIS-CONNECCT Knowledge Exchange Program DESCRIPTION:Features\nThe call for applications for the EATRIS-CONNECT knowledge exchange program offers grants of up to €1\,000 for researchers who wish to spend time at an eligible research institution\, with a focus on improving digital transformation in translational medicine. The program covers travel\, lodging\, and living expenses related to the visit. \nDigital transformation in translational medicine refers to the use of advanced digital technologies—such as data\, tools\, and services—to develop innovative solutions to unmet medical needs. \nThe call for applications is open to both EATRIS-CONNECT project partners and EATRIS organizations that are not officially part of the consortium. Expenses will be reimbursed upon completion of the visit and submission of the final report. \nRequirements\nWhat types of exchanges are funded? \nThere are no predefined exchange types\, but some examples include: \n\nDigital Transformation Literacy (DT Literacy): Individual staff exchanges between nodes to facilitate the transfer of knowledge related to digital solutions\, workflows\, and service delivery that support the development of translational medicine.\nWorkshops: group exchange of best practices or collaborative development of digital solutions.\nCollaborative initiatives: sharing experiences and ideas to drive joint digital transformation initiatives.\nOnline or virtual knowledge-sharing sessions: digital seminars\, webinars\, and other virtual events for sharing knowledge.\n\n\n\n\nHow to apply\nYou must submit the “Knowledge Exchange proposal” via this link to the application form. Before submitting it\, please verify your eligibility\, and we recommend that you read the program guide. \nThere is no deadline for submitting applications. URL:https://ibsal.es/en/evento/eatris-connecct-knowledge-exchange-program/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260505 DTEND;VALUE=DATE:20261001 DTSTAMP:20260512T063852Z CREATED:20260512T063852Z LAST-MODIFIED:20260512T063852Z UID:10002269-1777939200-1790812799@ibsal.es SUMMARY:36th Annual Mutual Médica Scholarship - Mutual Médica Foundation DESCRIPTION:Purpose\nThe Mutual Médica Foundation\, through its Impulsar(me) program\, is announcing a new call for applications for the Mutual Médica Research Grant\, intended for resident physicians who are in their final year or who have completed their residency within the last three years. The research must have potential applications in clinical practice. \nThe purpose of the scholarship is to support young researchers\, where “support” means helping young professionals bring to fruition research projects with the potential to bring about change\, especially at the most challenging time: at the beginning of their medical careers. \n  \nAmount\nThrough this scholarship\, the Mutual Médica Foundation supports physicians who are in their final year of the MIR program or who have completed their residency within the last three years. The winning research project will receive a grant of 25\,000 €\, and two runner-up prizes of 5\,000 € each will be awarded. \n  \nRequirements\nThe candidate must be a physician and be a member of one of the Official Medical Associations in Spain.\n— At the time of applying for the scholarship\, the candidate must be in their final year of residency\, or must have completed it this year or in one of the three preceding years\, from 2023 to 2025.\n— The research proposal must include the title of the project\, the name of the fellow\, the primary and secondary objectives\, the research hypothesis\, the materials and methodology to be used\, as well as the relevance and potential clinical implications of the research.\n— The work must be completed within a maximum of two years from the date the first grant is awarded.\n— Members of the Board of Directors of Mutual Médica and the Board of Trustees of the Mutual Médica Foundation\, as well as their family members\, are not eligible for the scholarship. \n  \nDocumentation\nTo be eligible for the grant\, the research physician must submit the following documentation:\n• Application form: Please fill out the form available at www.fundacionmutualmedica.com\n• Copy of ID card.\n• A certificate from the Director of Labor attesting to the candidate’s qualifications\, stating the Director’s commitment to monitor the candidate’s progress\, and verifying that the work can be completed within a period of 2 years.\n• A certificate from the director of the center or institution where the research is to be conducted\, confirming acceptance of the proposed work and stating that the technical capabilities necessary for its completion are available.\n• A document from the Clinical Research Ethics Committee of the relevant accrediting institution stating its approval\, if the study involves the participation of patients.\n• Resume.\n• Research Project. \nSubmission of documentation: \nAll documentation can be submitted as scanned copies:\n• Through the online form available at\nwww.fundacionmutualmedica.com (recommended option)\n• By email to premiosinvestigacion@fundacionmutualmedica.com\n• By certified mail to the secretariat of the Fundación Mutual Médica (Via Laietana\, 31\, 08003 Barcelona).\n• The deadline for submitting documentation is September 30\, 2026.\n• Copies of the duly signed originals of the Director of Labor’s Certificate\, the Center Director’s Certificate\, and the Ethics Committee Document must be provided. \n  \nComplete guidelines for the call for applications\nScholarship Application \n  URL:https://ibsal.es/en/evento/36th-annual-mutual-medica-scholarship-mutual-medica-foundation/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260514 DTEND;VALUE=DATE:20260916 DTSTAMP:20260515T121513Z CREATED:20260515T121513Z LAST-MODIFIED:20260515T121513Z UID:10002304-1778716800-1789516799@ibsal.es SUMMARY:Call for Entries: 3rd Aurelio Palomo Research Awards - Aless Lequio Foundation DESCRIPTION:Objective\nThe Aless Lequio Foundation invites research groups\, clinical trial teams\, and healthcare institutions to submit proposals to receive funding to support innovative projects aimed at finding a cure for Ewing sarcoma. The purpose of this call for proposals is to promote research and the development of effective treatments for this disease\, which affects a significant number of young people. \n  \nParticipants\n– Academic research groups. \n– Healthcare institutions. \n– Clinical trial teams. \n– Nonprofit organizations working in the field of oncology. \n  \nRequirements\nProposals must include the following information in order to be considered: objectives\, experimental design or scientific plan\, type of models to be used or methodology\, costs\, and timeline. \n– Project title. \n– Project description: Project objectives\, experimental design or scientific plan\, type of models to be used or methodology\, and relevance to the search for a cure for Ewing sarcoma. \n– Research Team: Resumes of the principal investigators and collaborators. \n– Detailed budget: Breakdown of the funding required to carry out the project and a justification for it. – Timeline: Project phases and estimated completion times. – Expected results: Potential impact on the research and treatment of Ewing sarcoma. \n  \nFunding\nThe Aless Lequio Foundation will award a grant of €50\,000 to the selected project\, which will be used exclusively to carry out the proposed activities. \n  \nAssessment Criteria\nProposals will be evaluated based on the following criteria: \n– Innovation and originality of the approach. \n– Technical and scientific feasibility. \n– Experience of the research team. \n– Potential impact on the treatment of Ewing’s sarcoma. \n  \nSubmission Deadlines\nProposals must be submitted by September 15\, 2026\, to the following email address: info@fundacionalesslequio.org. \n  \nContact\nhttps://fundacionalesslequio.org/ \ninfo@fundacionalesslequio.org \nPhone: 690966291 – 637747295 \n  \n  URL:https://ibsal.es/en/evento/call-for-entries-3rd-aurelio-palomo-research-awards-aless-lequio-foundation/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260701 DTEND;VALUE=DATE:20261009 DTSTAMP:20260903T122819Z CREATED:20260903T122819Z LAST-MODIFIED:20260903T122819Z UID:10002385-1782864000-1791503999@ibsal.es SUMMARY:American Society of Clinical Oncology\, Career Development Award DESCRIPTION:Features\nThe American Society of Clinical Oncology (ASCO) awards its Career Development Awards (CDA)\, which provide research funding to clinical investigators who have received their first faculty appointment as they work to establish an independent clinical cancer research program. \nThis is a mentored award\, and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus\, including a clinical research study and/or translational research involving human subjects. Proposals that focus primarily on in vitro or animal studies (even if clinically relevant) are not permitted. \nApplications in all areas of cancer research are accepted from U.S. and international applicants. \nThe grant period runs from July 1\, 2027\, through July 1\, 2030. The funding budget is $66\,600 per year. \nRequirements:\n\nApplicants must be physicians (MD\, DO\, or international equivalent).\nAt the time of submission\, applicants must be in their first through fourth year of their initial full-time faculty appointment in a clinical department at an academic medical institution. Eligible entry-level positions may include Instructor/Lecturer\, Assistant Professor\, or Assistant Member. \nApplicants must hold a valid\, active medical license in the country where the research will be conducted for the entire duration of the grant.\nApplicants must have completed productive postdoctoral research and demonstrated the ability to conduct independent\, investigator-initiated clinical research.\nApplicants must be current ASCO members or have submitted a membership application along with their grant application.\nApplicants must be able to devote at least 50% of their time to research during the grant period. This applies to their total research activity\, not just to the proposed project. \nApplicants must have a mentor from the sponsoring institution. If the mentor is not an ASCO member\, the application must include a letter of support from an ASCO member at the sponsoring institution. \nApplicants who hold other career development awards or institutional training grants may apply\, provided there is no scientific or budgetary overlap.\nApplicants should not have previously served as Principal Investigator on a major project grant\, such as an R01 or its international equivalent.\n\nHow to apply\nThe application must be submitted online through the ASCO Application Portal and must follow the instructions set forth in the Request for Proposals (RFP). \nThe deadline is October 8\, 2026. URL:https://ibsal.es/en/evento/american-society-of-clinical-oncology-career-development-award/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Helsinki:20260701T000000 DTEND;TZID=Europe/Helsinki:20261001T130000 DTSTAMP:20260715T085851Z CREATED:20260715T085851Z LAST-MODIFIED:20260715T085851Z UID:10002356-1782864000-1790859600@ibsal.es SUMMARY:Call for Proposals: R&D Projects - Pilot Studies on Public Policy - MICIU DESCRIPTION:Purpose\nThe R&I Project Call seeks to fund projects that promote research and innovation\, as well as scientific advice in public administration\, using scientific evidence to develop more effective policies. \n  \nDescription\nA public policy pilot study is a structured approach to learning—defined before the pilot begins—designed to generate knowledge about a public policy instrument (organizational\, regulatory\, financial\, or information-based). Pilot projects submitted in this subcategory must include a work plan and a series of milestones against which their implementation will be assessed. This plan must take into account the time needed to draw conclusions from the pilot. \nThe pilot project may involve significantly modifying a public administration tool used in the project (redesign); adapting a tool that has proven effective in another public administration to determine whether it is transferable (replication); or introducing an innovative tool (new or with significant improvements) compared to existing tools. \nThe study may consist of: \n\nTest the implementation of a tool in a small-scale pilot. These exploratory pilots are conducted when it is believed that the tool can be implemented as planned\, but it is still necessary to see how it actually works in the partner organization. They aim to determine whether the instrument can be implemented as planned; how beneficiaries respond to the instrument (their behavior or level of acceptance); or what results are likely to be obtained. These exploratory pilot studies help identify problems in the design and implementation of the instrument and provide an opportunity to refine the planning and the approach to evaluating the results.\nThe methodology of scientific research may be based\, for example\, on observational methods. \nConduct a small-scale pilot study to assess whether an instrument achieves its expected results. Pilot studies can be used to evaluate results. The evaluation should have the potential to influence the design of the instrument.\nThe evaluation methodology may be based\, for example\, on quasi-experimental methods or on experimental methods in a controlled setting\, such as randomized trials. The design of the instrument being tested in the pilot must be sufficiently developed to allow for the design of a randomized trial. For example\, it is necessary to ensure a sufficient sample size of participants in an intervention by conducting a preliminary study of demand. Studies based on randomized trials must analyze their ethical implications. \n\n\n  \nBeneficiaries\nResearch organizations\, universities\, healthcare institutions\, technology centers\, R&D centers\, and other entities that promote the transfer of R&D. To participate\, projects must be supported by a letter from a public administration committing to collaborate on the project. \n  \nScope of Assistance and Duration\nThe assistance covers\, among other things\, items such as: \n\nPersonnel costs for staff hired specifically for the project.\nTravel and per diem expenses.\nProcurement of equipment and supplies.\nConsulting\, advisory services\, data collection\, development of training programs\, project evaluation\, dissemination\, and publicity.\nRoom rentals\, conference planning\, events…\n\nGrants of up to 90% of the total project cost are available\, with a maximum limit of €100\,000 and a total estimated budget of three million euros. The project duration is a maximum of 24 months. \n  \nDeadlines\nThe application period will begin on July 1\, 2026\, and end on October 1\, 2026\, at 1:00 p.m. (Spanish peninsular time). \n  \nSubmission of Applications\nApplications must be submitted through the online application system available at the call for proposals’ website. Project leaders and the legal representatives of the applicant organizations must first register in the call for proposals’ Applicant Registration module and complete the corresponding application form. \nApplications must include a letter of support from the government agency responsible for the public policy whose design is to be improved. \n  \nCALL FOR SUBMISSIONS WEBSITE URL:https://ibsal.es/en/evento/call-for-proposals-rd-projects-pilot-studies-on-public-policy-miciu/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Helsinki:20260701T000000 DTEND;TZID=Europe/Helsinki:20261001T130000 DTSTAMP:20260715T085911Z CREATED:20260715T085911Z LAST-MODIFIED:20260715T085911Z UID:10002297-1782864000-1790859600@ibsal.es SUMMARY:Call for I+P Projects - Scientific research projects aimed at improving public policy design - MICIU DESCRIPTION:Purpose\nThe R&I Project Call seeks to fund projects that promote research and innovation\, as well as scientific advice in public administration\, using scientific evidence to develop more effective policies. \n  \nDescription\nA collaborative public administration can exchange knowledge with the requesting entity on a project that helps explore and better understand an issue that public policy seeks to address. This project would serve to update the assessment of the context of a public policy\, through\, for example\, foresight exercises or technology assessments. \nThe project may also aim to have the collaborating public administration review the rationale behind the intervention and its theory of change\, the objectives of the public policy\, or the selection of its instruments—for example\, through data mining and analysis. This data may be administrative data: the collaborating government agency may have data that it needs to organize\, analyze\, and integrate into a conceptual framework to guide the design of its public policies. Quasi-experimental methods\, for example\, may also be used to review the planning process. \n  \nBeneficiaries\nResearch organizations\, universities\, healthcare institutions\, technology centers\, R&D centers\, and other entities that promote the transfer of R&D. To participate\, projects must be supported by a letter from a public administration committing to collaborate on the project. \n  \nScope of Assistance and Duration\nThe assistance covers\, among other things\, items such as: \n\nPersonnel costs for staff hired specifically for the project.\nTravel and per diem expenses.\nProcurement of equipment and supplies.\nConsulting\, advisory services\, data collection\, development of training programs\, project evaluation\, dissemination\, and publicity.\nRoom rentals\, conference planning\, events…\n\nGrants of up to 90% of the total project cost are available\, with a maximum limit of €100\,000 and a total estimated budget of three million euros. The project duration is a maximum of 24 months. \n  \nDeadlines\nThe application period will begin on July 1\, 2026\, and end on October 1\, 2026\, at 1:00 p.m. (Spanish peninsular time). \n  \nSubmission of Applications\nApplications must be submitted through the online application system available at the call for proposals’ website. Project leaders and the legal representatives of the applicant organizations must first register in the call for proposals’ Applicant Registration module and complete the corresponding application form. \nApplications must include a letter of support from the government agency responsible for the public policy whose design is to be improved. \n  \nCALL FOR SUBMISSIONS WEBSITE URL:https://ibsal.es/en/evento/call-for-ip-projects-scientific-research-projects-aimed-at-improving-public-policy-design-miciu/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260716 DTEND;VALUE=DATE:20261116 DTSTAMP:20260717T081311Z CREATED:20260717T081311Z LAST-MODIFIED:20260717T081311Z UID:10002266-1784160000-1794787199@ibsal.es SUMMARY:“Salamanca Institute of Biomedical Research – Royal Academy of Medicine” Award DESCRIPTION:Description\nThe “Salamanca Biomedical Research Institute – Royal Academy of Medicine” Award for the best innovative work in health sciences conducted in 2026 by medical and non-medical professionals affiliated with the Salamanca Biomedical Research Institute (IBSAL). \n\n\n\n  \nAward\nThe prize consists of €1\,000 and a certificate. \n  \nPresentation\nTo submit an entry\, the candidate for the award must send the work and the relevant documentation (CVN and 3 copies of the work\, along with an electronic copy. In the case of multiple authors\, informed consent from all authors must be provided for the submission of the work to the award) for evaluation\, along with detailed information on the project’s current status. \nThe documents should be sent to the Academy’s email address\, ramsa@usal.es. \nThe documentation must be submitted by 1:00 p.m. on November 15\, 2026. \n  \nEvaluation\nThe judging panel\, composed of four Full Members of the RAMSA\, will issue its final evaluation based on the following criteria: the originality of the innovation—which may be basic\, clinical\, educational\, managerial\, etc.; its impact; other aspects that the committee deems relevant regarding the merits demonstrated by the author\, provided that they are related to the innovation. \n  \nRead the rules URL:https://ibsal.es/en/evento/salamanca-institute-of-biomedical-research-royal-academy-of-medicine-award/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260718 DTEND;VALUE=DATE:20260923 DTSTAMP:20260813T070323Z CREATED:20260813T070323Z LAST-MODIFIED:20260813T070323Z UID:10002358-1784332800-1790121599@ibsal.es SUMMARY:Call for Applications for Research Collaboration Scholarships at USAL Research Institutes and Affiliated Centers DESCRIPTION:Objective\nThe University of Salamanca is offering\, on a competitive basis\, 27 research assistantships at its research institutes and university-affiliated centers \nThese scholarships are intended to encourage students to begin engaging in research related to their current studies and to facilitate the future professional or research careers of students enrolled at the University of Salamanca during the 2026/2027 academic year who are about to complete their undergraduate degree or are currently enrolled in the first year of an official master’s program. \n  \nAmount\nThe amount of each scholarship is 2\,000 euros\, paid in a single installment\, which will be deposited into the bank account number provided for this purpose. Receipt of this scholarship does not exempt the recipient from paying the public fees for academic services. \nScholarship payments will be made from budget line 18.02.39.324M.D.07 of the University of Salamanca’s budget\, up to a maximum of 54\,000 euros. \n\n  \nDuration and Commitment\nThe collaboration will last seven and a half months from the start date indicated in the Resolution and will require three hours of on-site work per day\, in accordance with the terms set forth in the collaboration proposal submitted. \n  \nIncompatibilities\nThese scholarships are incompatible with any other scholarship or financial aid awarded for the current academic year by public or private organizations for the same or a similar purpose\, as well as with any contractual compensation that would prevent the fulfillment of the obligations. \nThey will be compatible with the general scholarships for the 2026–2027 academic year offered by the Ministry of Education\, Vocational Training\, and Sports for college students\, as well as with academic excellence programs. \n  \nApplications\nThe application must be completed using the form available on the University of Salamanca’s Online Portal\, by logging in with any of the authentication methods listed in the following online procedure (including IdUsal): \nhttps://sede.usal.es/procedimientos?param1=BECOIN \nThe applicant must ensure that the process is completed correctly and download the registered receipt. The process is complete when the following message appears on the online portal: “Process completed. You have completed all your tasks. Your application for Research Institute and University-Affiliated Center Collaboration Scholarships has been submitted for processing.” \nApplications that do not complete the established submission process will not be considered. Applicants must obtain the application receipt\, which must be retained to prove\, if necessary\, that the application was submitted within the established time frame and in the prescribed manner. \nIf the same person submits more than one scholarship application\, only the most recent one will be processed. \nNo changes to the application will be accepted after the application deadline has passed. \nApplicants may apply to a maximum of three different high schools or schools. \nSubmission of the application implies acceptance of the terms and conditions of the call for applications and\, specifically\, authorization for the publication of the provisional and final lists of candidates for the process\, including their grade point averages and the score awarded to the collaborative project\, as well as the location where the work will be performed and the amount of the grant awarded\, in accordance with the provisions of the regulations governing grants and the regulations on the protection of personal data. \n  \nSubmission Deadline\nThe application period will run from July 18\, 2026\, through September 22\, 2026\, inclusive. \n  \nCALL FOR APPLICATIONS \nBOCYL EXTRACT \n  \n  URL:https://ibsal.es/en/evento/call-for-applications-for-research-collaboration-scholarships-at-usal-research-institutes-and-affiliated-centers/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260720 DTEND;VALUE=DATE:20260921 DTSTAMP:20260722T093050Z CREATED:20260722T093050Z LAST-MODIFIED:20260722T093050Z UID:10002309-1784505600-1789948799@ibsal.es SUMMARY:Call for Proposals: Clinical Research and Medical Innovation - Duponte Program DESCRIPTION:Objective\nThe goal is to promote research projects with a significant impact on clinical practice that contribute to the advancement of personalized medicine\, with a particular focus on genomic alterations and the development of new technologies and therapeutic strategies. \n  \nParticipants\nThis call for proposals is open to universities\, hospitals\, and facilities within the National Health System\, as well as research centers and institutes and biotechnology companies. \n  \nPriority Areas\nThe priority areas for research projects are as follows: \n— Genomics \n— Bioinformatics \n— Clinical Pharmacogenomics \n— Rare Diseases \n  \nImportant Dates\nApplication period begins: 20/07/2026 \nApplication deadline: September 20\, 2026 \nResolution: October 2026 \n  \nApplication Process\nTo access the application\, you must do so through the call for applications website byclicking”here.” \nOr by visiting: https://www.duponteconvoca.com/ \nThe process consists of three steps: \n1. Complete the registration as Principal Investigator and attach your resume. \n2. Submit the proposal by accessing your profile and completing the proposal with all the required documentation. \n3. Receive the results: The proposal will be reviewed by independent experts based on scientific\, technical\, clinical\, and regulatory criteria. \n  \nCALL FOR SUBMISSIONS WEBSITE URL:https://ibsal.es/en/evento/call-for-proposals-clinical-research-and-medical-innovation-duponte-program/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260803 DTEND;VALUE=DATE:20260924 DTSTAMP:20260903T081857Z CREATED:20260903T075747Z LAST-MODIFIED:20260903T081857Z UID:10002374-1785715200-1790207999@ibsal.es SUMMARY:BBRF Distinguished Investigator Grants for 2027 DESCRIPTION:Features\nThe Brain & Behavior Research Foundation is now accepting applications for the 2027 Distinguished Investigator (DI) Grant. This program supports established basic and clinical researchers with a strong track record of research achievements to pursue highly innovative projects aimed at improving the understanding and treatment of severe mental illness and other brain and behavioral disorders. If successful\, these grants could lead to further funding from other sources. These grants are among the most competitive in mental health research and demonstrate the power of investigator-initiated research to generate new and creative ideas. \nEligible areas include addiction\, ADHD\, anxiety\, autism\, bipolar disorder\, borderline personality disorder\, depression\, eating disorders\, OCD\, PTSD\, schizophrenia\, and suicide prevention. \nThe available funding is up to $100\,000 for a one-year period. \nMore information is available at this link. \nRequirements:\n\nApplicants must be a full professor (or equivalent) and maintain peer-reviewed\, competitively funded scientific programs.\nApplicants may not receive the award a second time.\n\nHow to apply\nApplications must be submitted electronically through the BBRF website. Deadline: Wednesday\, September 23\, 2026\, at 11:59 p.m. Eastern URL:https://ibsal.es/en/evento/bbrf-distinguished-investigator-grants-for-2027/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260803 DTEND;VALUE=DATE:20261106 DTSTAMP:20260903T093329Z CREATED:20260903T090320Z LAST-MODIFIED:20260903T093329Z UID:10002378-1785715200-1793923199@ibsal.es SUMMARY:BREAKTHROUGH T1D\, Type 1 Diabetes Research DESCRIPTION:Features\n  \nThe Breakthrough T1D organization is now accepting applications for project concepts. This is a semi-annual call for Letters of Intent for Strategic Research Agreements that address Breakthrough T1D’s current research strategy. \nThis call supports individual and collaborative projects that address critical gaps and challenges in type 1 diabetes research. \nRequirements:\n\nProposals may be submitted by nonprofit or public organizations. Generally\, for-profit organizations will not be considered\, except under special circumstances. \nApplicants must hold an MD\, DMD\, DVM\, DO\, PhD\, or equivalent degree and hold a faculty position or equivalent at a college\, university\, medical school\, company\, or other research facility.\n\nHow to apply\nThe application process consists of two steps. Letters of Intent (LOIs) must be submitted through the RMS360 portal. Letters of Intent and full proposals are due by 5:00 p.m. Eastern Time on the following deadline dates: \nRound 1: \nLetters of Intent due November 5\, 2026 (link) \nNotification by December 17\, 2026 \nRound 2: \nLetters of Intent are due on May 6\, 2027 \nNotification by URL:https://ibsal.es/en/evento/breakthrough-t1d-type-1-diabetes-research/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260818 DTEND;VALUE=DATE:20260930 DTSTAMP:20260903T104823Z CREATED:20260903T104823Z LAST-MODIFIED:20260903T104823Z UID:10002379-1787011200-1790726399@ibsal.es SUMMARY:Gates Foundation Innovations in Low-Cost and Simplified Pathogen Sequencing Workflows DESCRIPTION:Features\nThis Grand Challenge is co-funded by the Gates Foundation and the Temasek Foundation\, and will be managed by the United Nations Foundation. \nThis call supports the development of low-cost\, simplified pathogen sequencing workflows for routine public health use in low- and middle-income countries (LMICs)\, with the aim of reducing total sample-to-sequence costs to approximately US$1–10 per sample. Priority areas include viral pathogens\, malaria\, tuberculosis\, and bacterial or microbial pathogens relevant to antimicrobial resistance and transmission surveillance. \nThe call prioritizes technological and methodological innovation in sequencing workflows rather than new sequencing hardware. Solutions should be compatible with existing platforms\, simplify protocols\, and be suitable for routine public health use in LMICs. \nProjects are grouped into three tiers based on their stage of development: \n\nTier 1 – Early-stage feasibility: Higher-risk or early-stage concepts focused on feasibility testing\, assay or workflow prototyping\, and initial validation of cost reduction.\nTier 2 – Mid-stage development: Projects with preliminary evidence that aim to integrate and optimize the workflow\, expand its applicability to additional pathogens\, and generate robust performance and cost data.\nTier 3 – Advanced development and validation: More mature solutions focused on refinement\, optimization\, and validation in real-world public health settings in low- and middle-income countries (LMICs).\n\nUp to $300\,000 (Tier 1)\, $600\,000 (Tier 2)\, or $800\,000 (Tier 3). \nRequirements:\nOpen to research institutes\, nonprofit organizations\, for-profit companies\, international organizations\, government agencies\, and academic institutions. \nHow to apply\nBefore applying\, applicants should review the supporting documents for this Grand Challenge\, including the rules and guidelines\, application instructions\, and frequently asked questions. URL:https://ibsal.es/en/evento/gates-foundation-innovations-in-low-cost-and-simplified-pathogen-sequencing-workflows/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261103 DTSTAMP:20260903T110132Z CREATED:20260903T110132Z LAST-MODIFIED:20260903T110132Z UID:10002386-1788220800-1793663999@ibsal.es SUMMARY:EASD Albert Renold Travel Fellowship Program DESCRIPTION:Features\nThe EASD Albert Renold Travel Fellowships enable scientists and clinicians to travel and stay at other institutions in order to learn specific techniques or clinical skills required for the advancement of their diabetes research project and not available at their home institution. \nThe home institution and/or the host institution must be based in Europe or a country associated with Europe (for a detailed list of countries\, please see here); both must be nonprofit organizations\, and each must be located in a different country. Applicants must be employed at their home institution during the term of the award. \nThe duration of the stay may be up to 3 months. The requested amount for each fellowship may be up to 10\,000 euros. \nRequirements:\n\nApplicants must be early-career scientists or clinicians who\, as of January 1 of the year the fellowship is awarded\, have completed their most recent degree (PhD\, MSc\, or MD) within the past 7 years. Eligibility may be extended for duly justified career breaks. Fellows may not hold a permanent appointment. \nThe home and/or host institution must be based in Europe or a country associated with Europe; both must be nonprofit organizations\, and each must be located in a different country. Applicants must be employed at their home institution during the duration of the grant. \nSuccessful applicants must travel within nine months of receiving the award.\nFunds cannot be used to help pay for part of a longer stay.\nAwardees may not receive a second fellowship within two years of receiving their award.\nApplicants must be members of the EASD in good standing.\n\nHow to apply\nApplications must be submitted through the EFSD portal by 12:00 p.m. (CET) on the deadline\, November 2\, 2026. URL:https://ibsal.es/en/evento/easd-albert-renold-travel-fellowship-program-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261117 DTSTAMP:20260903T112956Z CREATED:20260903T112956Z LAST-MODIFIED:20260903T112956Z UID:10002387-1788220800-1794873599@ibsal.es SUMMARY:German Academic Exchange Service (DAAD) Binationally Supervised Doctoral Degrees / Cotutelle DESCRIPTION:Features\nThe Deutscher Akademischer Austauschdienst (DAAD) / German Academic Exchange Service offers the“Bi-nationally Supervised Doctoral Degrees / Cotutelle” program. This program provides doctoral candidates with the opportunity to pursue a bi-national doctoral degree at their home university and at a university in Germany. \nThere are two types of doctoral programs: \n\nOption a) Doctorate with binational supervision (“sandwich model”): The PhD project is supervised jointly by an academic advisor at the home university and another at the host institution in Germany. The doctoral degree is awarded by the home university. \nOption b) Joint Doctoral Program: The PhD project is carried out jointly at the home university and a university in Germany under an individual joint supervision agreement established specifically for the project. Upon successful completion\, the two universities jointly award the doctoral degree. \n\n  \nThe scholarship provides €1\,400 per month for the research stay in Germany\, for a period of 7 to 24 months. \nIt also includes a travel allowance\, a €460 research allowance\, and health\, accident\, and liability insurance. Additional allowances may be available depending on the applicant’s circumstances. \nRequirements:\n\nAs a general rule\, the most recent university degree must have been earned no more than 6 years prior to the application deadline.\nIf the doctoral program has already begun\, it must have started no more than 3 years before the application deadline.\nApplicants must not have been residents of Germany for more than 15 months as of the application deadline.\nFor the “Sandwich Model\,” applicants must hold a master’s degree or a Diplom (or\, in exceptional cases\, a bachelor’s degree) by the start of the funding period.\nFor the “Cotutelle model\,” applicants must have been admitted to a doctoral program by the start of the funding period.\n\n\nHow to apply\nApplications must be submitted online via the DAAD Portal—by clicking the “SUBMIT AN APPLICATION” button. Applicants must complete the online application form and upload the required supporting documents\, including the research proposal\, CV\, motivation letter\, academic documents\, and the confirmation from the German supervisor. \nFor the Cotutelle option\, an individual Cotutelle agreement between the home university and the German university is required before the funding period begins. The application deadline is November 16\, 2026. URL:https://ibsal.es/en/evento/german-academic-exchange-service-daad-binationally-supervised-doctoral-degrees-cotutelle-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260907 DTEND;VALUE=DATE:20261107 DTSTAMP:20260903T084350Z CREATED:20260903T082838Z LAST-MODIFIED:20260903T084350Z UID:10002376-1788739200-1794009599@ibsal.es SUMMARY:Sarcoma Foundation of America (SFA) Research Grants DESCRIPTION:Features\nThe Sarcoma Foundation of America Research Grants support researchers conducting preclinical\, translational\, and clinical research on the etiology\, molecular biology\, pathogenesis\, diagnosis\, and treatment of human sarcomas. This program supports research and promotes awareness and advocacy for sarcoma patients and their families. The goal of the SFA grant program is to support research that leads to improved treatment options for sarcoma patients. The SFA encourages applications from ALL areas of sarcoma research. \nThe total award amount is $75\,000 for one year. The grants are awarded on an annual basis from July 1\, 2027\, to June 30\, 2028. SFA encourages applications in ALL areas of sarcoma research from U.S. and international applicants. \nRequirements:\n\nApplicants must hold an MD\, DO\, PhD\, or international equivalent—whether in the U.S. or abroad—and possess the skills\, knowledge\, and resources necessary to carry out the proposed sarcoma research;\nOnly one applicant may be designated as the principal investigator (PI) for each grant. The PI is responsible for the overall management\, coordination\, and oversight of the research\, including all deliverables; \nApplications from researchers outside the U.S. must be able to provide a budget and accept funds in U.S. dollars;\nReturning SFA principal investigators and organizational grantees must comply with all previous SFA grant deliverables\n\nHow to apply\nThe SFA Research Grant Program is a two-stage process. All applicants must submit a Letter of Intent (LOI). Only the highest-ranked LOIs will be invited to submit full applications. \nThe deadline for submitting the Letter of Intent is November 6\, 2026\, at 11:59 p.m. EST. The link to Proposal Central for Applicants & Awardees. URL:https://ibsal.es/en/evento/sarcoma-foundation-of-america-sfa-research-grants/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260909 DTEND;VALUE=DATE:20261117 DTSTAMP:20260909T115154Z CREATED:20260909T115154Z LAST-MODIFIED:20260909T115154Z UID:10002380-1788912000-1794873599@ibsal.es SUMMARY:DKMS John Hansen Research Grant 2026 DESCRIPTION:Features\nThe DKMS John Hansen Research Grant provides funding for research into hematopoietic stem cell transplantation and cell therapy for hematological diseases. The application period for the 2027 grant is now open. \nThe DKMS John Hansen Research Grant supports promising young scientists conducting research in the field of blood cancer\, with a particular focus on hematopoietic stem cell transplantation and cell therapy for hematological diseases. Projects primarily focused on product development\, commercialization\, or other commercial activities are not eligible. \nThe grant may cover\, among other things\, consumables\, the principal investigator’s (PI) own position\, a Ph.D. student dedicated to the project\, technicians who devote at least 30% of their time to the project\, relevant training\, and certain publication costs. Up to EUR 2\,500 per year can be used for travel\, lodging\, and registration fees for a scientific conference to present project results\, and up to EUR 10\,000 may be allocated for reasonable publication costs\, including open-access fees. \nThe grant lasts up to 3 years. Each annual funding period runs from July 1 to June 30 of the following year. The funding amounts to up to EUR 240\,000\, with a maximum of EUR 80\,000 per year. \nRequirements:\n\nApplicants from all countries are welcome to apply.\nApplicants must have earned a doctoral degree (PhD\, MD\, or equivalent) in a field relevant to the grant within the 10 years preceding the start of the call for proposals.\nApplicants must appoint a supervisor\, ideally a senior scientist at the host institution with expertise relevant to the proposed research.\n\nHow to apply\nApplicants must submit: \n\ninformation about the applicant;\na description of the research project; and\na budget plan\, following the application instructions.\n\nApplications must be submitted via email to grant@dkms.org by November 16\, 2026\, at 11:59 p.m. (Central European Time). URL:https://ibsal.es/en/evento/dkms-john-hansen-research-grant-2026/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20260914T130000 DTEND;TZID=UTC:20260914T143000 DTSTAMP:20260909T062757Z CREATED:20260909T062748Z LAST-MODIFIED:20260909T062757Z UID:10002392-1789390800-1789396200@ibsal.es SUMMARY:Information Session: Call for Research Proposals from the Regional Health Administration 2026 DESCRIPTION:Date: Monday\, September 14\, 2026\nTime: 1:00 p.m. – 2:30 p.m.\nLocation: Auditorium\, Salamanca University Healthcare Complex \n\n  URL:https://ibsal.es/en/evento/information-session-call-for-research-proposals-from-the-regional-health-administration-2026/ LOCATION:Assembly Hall of the Complejo Asistencial Universitario of Salamanca\, P.º de San Vicente\, 182\, Salamanca\, Salamanca\, 37007\, Spain CATEGORIES:Event ATTACH;FMTTYPE=image/jpeg:https://ibsal.es/wp-content/uploads/2026/09/Jornada-GRS-2026-VERTICAL.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20260915T083000 DTEND;TZID=UTC:20260915T093000 DTSTAMP:20260907T091110Z CREATED:20260907T091110Z LAST-MODIFIED:20260907T091110Z UID:10002388-1789461000-1789464600@ibsal.es SUMMARY:PREDOC Seminar: Development of a CRISPR-Cas-Based Gene Therapy Strategy for Modeling and Treating Protein Misfolding Diseases DESCRIPTION:Speaker: Nora González Martín (TGYC-07—Genomic Editing and Animal Models)\nDate: Tuesday\, September 15\, 2026\nTime: 8:30–9:30 a.m.\nLocation: Auditorium. School of Medicine\, University of Salamanca \n\n  URL:https://ibsal.es/en/evento/predoc-seminar-development-of-a-crispr-cas-based-gene-therapy-strategy-for-modeling-and-treating-protein-misfolding-diseases/ LOCATION:Hall of Degrees. Faculty of Medicine of the University of Salamanca.\, C. Alfonso X el Sabio\, s/n\, Salamanca\, Salamanca\, 37007\, Spain CATEGORIES:Event ATTACH;FMTTYPE=image/jpeg:https://ibsal.es/wp-content/uploads/2026/09/Seminario-predoc-15.09.2026-scaled.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20260922T090000 DTEND;TZID=UTC:20260922T120000 DTSTAMP:20260901T104043Z CREATED:20260831T120159Z LAST-MODIFIED:20260901T104043Z UID:10002359-1790067600-1790078400@ibsal.es SUMMARY:Workshop on Searching the Patent System DESCRIPTION:  \nEnrollment: \nREGISTRATION: \nThe registration deadline is Friday\, September 18\, 2026. Please register individually through our website: \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nPlease note that you will only be considered enrolled in the course once you receive the confirmation email\, as there is a limit of 25 spots. \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  \n  URL:https://ibsal.es/en/evento/workshop-on-searching-the-patent-system/ LOCATION:Computer Room 1. Dioscorides Building\, Computer Lab I\, Diocórides Building\, Salamanca CATEGORIES:IBSAL Course ATTACH;FMTTYPE=image/jpeg:https://ibsal.es/wp-content/uploads/2026/08/Taller-de-busquedas-en-el-sistema-de-patentes-scaled.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20260924T081500 DTEND;TZID=UTC:20261210T094500 DTSTAMP:20260901T110351Z CREATED:20260831T120427Z LAST-MODIFIED:20260901T110351Z UID:10002361-1790237700-1796895900@ibsal.es SUMMARY:2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Castile and León DESCRIPTION:“Second Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Castile and León” \n  \nObjective: \n\n\n\nTo determine therapeutic management and experience in treating patients with severe chronic non-polypoid sinusitis (CNPS). \nTo establish criteria for the indication and treatment of various nasosinusal conditions (epistaxis\, septopyramidal deviation\, eosinophilic otitis).\n\n\n\n  \nSpecific objectives: \n  \n\n\n\n-Establish a treatment strategy\, incorporating biologics into the current treatment algorithm. \n-Evaluation of real-world outcomes of treatment with biologic drugs. \n-Establish a standardized approach to the management of epistaxis in the emergency department. \n-Establish the criteria for surgical indication and the surgical techniques for patients with septopyramidal deviation.\n\n\n\n  \nLocation: \nTEAMS link. \n  \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nSPEAKER \n\n\n Thursday\, September 24\, 2026\n8.15-9.45\n  \n‘s Septorhinoplasty Online \n \nMs. María Gil Melcón \nHead of the Otolaryngology Section. CAUSA \n\n\n Thursday\, November 5\, 26\n8.15-9.45\n  \nEosinophilic Otitis: Diagnosis\, Treatment\, and Outcomes in CAUSA \nOnline \n \nMs. Susana Marcos Alonso \nL.E.A. Otolaryngology. CAUSE \n\n\n Thursday\, December 10\, 2026\n8.15-9.45\nDupilumab in Real-World Practice in CAUSA \nOnline.\nMr. Juan Carlos del Pozo de Dios \nL.E.A. Otolaryngology. CAUSE. \n\n\n\n  \nEnrollment: \nREGISTRATION: \nThe registration deadline is Tuesday\, September 22\, 2026; you must register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/2nd-edition-of-the-continuing-education-program-on-inflammatory-nasal-and-sinus-diseases_castile-and-leon/ CATEGORIES:Course ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/08/Regeneron-logo--scaled.png END:VEVENT END:VCALENDAR